Quidel receives expanded approval for COVID-19 test

By LabPulse.com staff writers

March 27, 2020 -- The U.S. Food and Drug Administration has expanded Quidel's emergency use authorization for the company's Lyra SARS-CoV-2 assay, a real-time reverse transcription polymerase chain reaction (RT-PCR) test for the novel coronavirus.

The expanded authorization allows clinicians to use the Lyra assay with three new thermocyclers: Applied Biosystems 7500 Standard, Roche LightCycler 480, and Qiagen Rotor-Gene Q.

The company previously announced on March 18 that it had received emergency use authorization for the Lyra SARS-CoV-2 test. The initial authorization granted Quidel the use of Lyra for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs. However, the U.S. Centers for Disease Control and Prevention has since expanded specimen options to include nasal and nasal turbinate swabs, the company noted.

Quidel also announced it has received the CE Mark in Europe and authorization from Health Canada to market and sell the assay.

Molecular testing and COVID-19: Where are we now?
As the COVID-19 pandemic accelerates, attention has been focused on how to effectively scale up the diagnostic testing that is needed to correctly manage...
What the just-passed CARES Act means for U.S. labs and IVD vendors
The U.S. Senate has passed a $2.2 trillion spending bill -- dubbed the CARES Act -- designed to provide economic stimulus and fund the effort to combat...
T2 adds coronavirus test to panels, per health network deal
T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
PerkinElmer gets regulatory nod in U.S. for coronavirus test
PerkinElmer is among the latest vendors to receive an emergency use authorization from the U.S. Food and Drug Administration for a reverse transcription...
Quidel coronavirus test granted emergency authorization
Quidel has received emergency use authorization from the U.S. Food and Drug Administration to market its Lyra SARS-CoV-2 assay, a real-time reverse transcription...

Copyright © 2020 LabPulse.com

Last Updated np 3/26/2020 4:22:40 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current